Worldwide burden of cancer attributable to HPV by site, country and HPV type

International Journal of Cancer

Volumn 141, Issue 4, 2017, Pages 664-670

  de Martel, Catherine ^a   Plummer, Martyn ^a   Vignat, Jerome ^a   Franceschi, Silvia ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

attributable fraction; cancer; human papillomavirus; prevention; vaccine

Indexed keywords

ADULT; AFRICA SOUTH OF THE SAHARA; AGED; ANUS CANCER; ARTICLE; AUSTRALIA AND NEW ZEALAND; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; GENITAL TRACT CANCER; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; INDIA; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; OROPHARYNX CANCER; PENIS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; UNITED STATES; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER; WART VIRUS; ANUS TUMOR; AUSTRALIA; ISOLATION AND PURIFICATION; NEW ZEALAND; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTIONS; PENIS TUMOR; PREVALENCE; SEXUAL DEVELOPMENT; UTERINE CERVIX TUMOR; VIROLOGY;

AFRICA SOUTH OF THE SAHARA; ANUS NEOPLASMS; AUSTRALIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INDIA; MALE; NEW ZEALAND; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PENILE NEOPLASMS; PREVALENCE; SEX CHARACTERISTICS; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 85020285847     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30716     Document Type: Article

References (27)

1. Jit M, Brisson M, Portnoy A, et al. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health 2014;2:e406–14.
2. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016;4:e453–63.
3. Santesso N, Mustafa RA, Schunemann HJ, et al. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. Int J Gynaecol Obstet 2016;132:252–8.
4. IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 1995;64:1–378 (Accessed May 12, 2015 at http://monographs.iarc.fr/ENG/Monographs/vol64/index.php.)
5. IARC. Human Papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007;90:1–670 (Accessed May 12, 2015 at http://monographs.iarc.fr/ENG/Monographs/vol90/index.php.)
6. IARC. Biological Agents. IARC Monogr Eval Carcinog Risks Hum 2012;100B:1–475 (Accessed May 12, 2015 at http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php.)
7. Beachler DC, Kreimer AR, Schiffman M, et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral hpv infection. J Natl Cancer Inst 2016;108
8. Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016;4:e609–16.
9. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, 2013 (Accessed May 20, 2015, at http://GLOBOCAN.iarc.fr.)
10. Forman D, Bray F, Brewster DH, et al. Cancer Incidence in Five Continents, Vol. X. International Agency for Research on Cancer, 2013 (Accessed 20 May, 2015, at http://ci5.iarc.fr.)
11. United Nations Development Program. Human Development Report 2013: The Rise of the South: Human Progress in a Diverse World. New York: UN Development Program, 2013 (Accessed May 20, 2015, at http://hdr.undp.org/en/2013-report.)
12. Alemany L, Cubilla A, Halec G, et al. Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol 2016;69:953–61.
13. Castellsague X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 2016;108:djv403.
14. Serrano B, de Sanjose S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer 2015;51:1732–41.
15. Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus and cervical cancer. Lancet 2013;382:889–99.
16. Marur S, D'Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781–9.
17. Rietbergen MM, Braakhuis BJ, Moukhtari N, et al. No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors. J Oral Pathol Med 2014;43:137–42.
18. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294–301.
19. Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 2017; doi: 10.1038/nature21386.
20. de Martel C, Shiels MS, Franceschi S, et al. Cancers attributable to infections among adults with HIV in the United States. AIDS 2015;29:2173–81.
21. Bosch FX, Robles C, Diaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016;13:119–32.
22. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349–59.
23. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013;10:400–10.
24. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 2015;16:775–86.
25. Cameron RL, Kavanagh K, Pan J, et al. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. Emerg Infect Dis 2016;22:56–64.
26. Clifford GM, de Vuyst H, Tenet V, et al. Effect of HIV infection on human papillomavirus types causing invasive cervical cancer in Africa. J Acquir Immune Defic Syndr 2016;73:332–9.
27. Pagliusi S, Ting CC, Khomvilai S. Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand. Vaccine 2016;34:3562–7.